Literature DB >> 20701860

Seroprevalence study of HCV among hospitalized intravenous drug users in Ahvaz, Iran (2001-2006).

Seyed Mohammad Alavi1, Leila Alavi.   

Abstract

BACKGROUND AND AIMS: Prevalence of hepatitis C virus (HCV) in intravenous drug users (IDU) varies in different areas according to socioeconomic and geographical circumstances. The present study was performed to determine seroprevalence of HCV in IDU individuals in Ahvaz, Iran.
MATERIALS AND METHODS: 142 IDU patients were included in this retrospective study in Ahvaz southwest Iran from 2001 to 2006. Patients were placed in two groups determined by HCV Ab positive or negative status. Data were analyzed using SPSS for Windows (version 11.5; SPSS Inc., USA) software.
RESULTS: Out of total 142 cases, 74 persons (52.11%) had a positive HCV-Ab test according to the ELISA method. There was no difference in age, sex, level of education, residency and co-infection with HIV and hepatitis B virus between HCV-Ab positive (HAP) and HCV-Ab negative (HAN) groups (p>0.05). HCV-Ab positivity was significantly related to imprisonment and duration spent in prison [OR: 3.22, 95% (CI) 2.61-3.76, p<0.0001].
CONCLUSION: Patients with IDU constitute a high-risk group for acquisition of HCV infection. Transmission of HCV via sharing syringe and needle as well as blood transfusion has been a significant source of hepatitis C infection for patients with intravenous drug addiction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20701860     DOI: 10.1016/j.jiph.2009.01.001

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  9 in total

1.  Hepatitis C Virus Coinfection in People With Human Immunodeficiency Virus in Iran: A Systematic Review and Meta-Analysis.

Authors:  Seyedeh-Kiana Razavi-Amoli; Abbas Alipour
Journal:  Open Forum Infect Dis       Date:  2022-09-21       Impact factor: 4.423

2.  Hepatitis C among Intravenous Drug Users in Isfahan, Iran: a Study of Seroprevalence and Risk Factors.

Authors:  Zary Nokhodian; Marjan Meshkati; Peyman Adibi; Behrooz Ataei; Nazila Kassaian; Majid Yaran; Parisa Shoaei; Razieh Hassannejad
Journal:  Int J Prev Med       Date:  2012-03

3.  Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa.

Authors:  Ghina R Mumtaz; Helen A Weiss; Peter Vickerman; Natasha Larke; Laith J Abu-Raddad
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

Review 4.  The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses.

Authors:  Sarwat Mahmud; Vajiheh Akbarzadeh; Laith J Abu-Raddad
Journal:  Sci Rep       Date:  2018-01-09       Impact factor: 4.379

5.  A systematic review and meta-analysis of the prevalence of hepatitis C virus infection in people who inject drugs in Iran.

Authors:  Masoud Behzadifar; Meysam Behzadifar; Nicola Luigi Bragazzi
Journal:  BMC Public Health       Date:  2020-01-14       Impact factor: 3.295

Review 6.  Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis.

Authors:  Abdolhalim Rajabi; Heidar Sharafi; Seyed Moayed Alavian
Journal:  Harm Reduct J       Date:  2021-01-22

Review 7.  Prevalence of HIV and HCV among injecting drug users in three selected WHO-EMRO countries: a meta-analysis.

Authors:  Shah Jahan Shayan; Rajab Nazari; Frank Kiwanuka
Journal:  Harm Reduct J       Date:  2021-05-27

Review 8.  HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis.

Authors:  Ghina R Mumtaz; Helen A Weiss; Sara L Thomas; Suzanne Riome; Hamidreza Setayesh; Gabriele Riedner; Iris Semini; Oussama Tawil; Francisca Ayodeji Akala; David Wilson; Laith J Abu-Raddad
Journal:  PLoS Med       Date:  2014-06-17       Impact factor: 11.069

9.  The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa.

Authors:  Sarwat Mahmud; Ghina R Mumtaz; Hiam Chemaitelly; Zaina Al Kanaani; Silva P Kouyoumjian; Joumana G Hermez; Laith J Abu-Raddad
Journal:  Addiction       Date:  2020-02-03       Impact factor: 6.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.